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ABSTRACT 
In this study, we investigated whether childhood cancer survival in Switzerland is 
influenced by socioeconomic status (SES), and if disparities vary by type of cancer 
and definition of SES (parental education, living condition, area-based SES). Using 
Cox proportional hazards models, we analyzed 5-year cumulative mortality in all 
patients registered in the Swiss Childhood Cancer Registry diagnosed 1991-2006 
below 16 years. Information on SES was extracted from the Swiss census by 
probabilistic record linkage. The study included 1602 children (33% with leukemia, 
20% with lymphoma, 22% with central nervous system (CNS) tumors); with an overall 
5-year survival of 77% (95%CI 75-79%). Higher SES, particularly parents’ education, 
was associated with a lower 5-year cumulative mortality. Results varied by type of 
cancer with no association for leukemia and particularly strong effects for CNS tumor 
patients, where mortality hazard ratios for the different SES indicators, comparing the 
highest with the lowest group, ranged from 0.48 (95%CI: 0.28–0.81) to 0.71 (95%CI: 
0.44–1.15). We conclude that even in Switzerland with a high quality health care 
system and mandatory health insurance, socioeconomic differences in childhood 
cancer survival persist. Factors causing these survival differences have to be further 
explored, to facilitate universal access to optimal treatment and finally eliminate social 
inequalities in childhood cancer survival. 
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INTRODUCTION 
In Europe and the US, cancer is a leading cause of childhood death 1-3. Although 
overall 5-year survival increased in the last decades reaching now 81% in 
Switzerland, large differences between types of cancer and regions remain 4. In 
adults and adolescents, socioeconomic status (SES) determines long-term outcome 
after cancer 5-7. For childhood cancer in contrast, data on survival and SES are 
scarce and contradictory. In a recent systematic review the authors concluded that 
socioeconomic gradients in which low SES is associated with inferior childhood 
cancer survival are ubiquitous in low income countries and common in high income 
countries 8. The review further showed that a majority of the European studies were 
focused on hematologic malignancies and many studies especially from the UK 
evaluated area-based SES measures. According to the Organisation for Economic 
Co-operation and Development (OECD) 
(http://www.oecdbetterlifeindex.org/countries/switzerland/), Switzerland is a high 
income country with an above average quality of its educational system, mandatory 
health insurance and a high quality healthcare system, resulting in one of the 
highest life expectancies in Europe 3, 9, 10. Despite all this, it has notable differences 
in mortality and life expectancy between regions and by socioeconomic status, at 
least in the German speaking part of Switzerland 11, 12 . 
 
In this study, which linked the Swiss Childhood Cancer Registry to National census 
records, we investigated whether childhood cancer survival in Switzerland is 
influenced by the socioeconomic status of the patient. We examined several tumor 
groups (leukemia, acute lymphoblastic leukemia (ALL), lymphoma, central nervous 
system (CNS) tumors, bone and soft tissue tumors, and embryonal tumors) to 
assess potential variation by tumor type; and we applied distinct definitions of SES 
(parents’ education, living condition, area-based SES) to describe their potentially 
modifying effects on cancer survival.  
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MATERIAL AND METHODS 
Study Population and Data Sources 
The Swiss Childhood Cancer Registry 
In this nationwide survival study, we included all childhood cancer patients diagnosed 
between 1991 and 2006 at an age <16 years who were registered in the Swiss 
Childhood Cancer Registry (SCCR, http://childhoodcancerregistry.ch/) 13, 14. The SCCR 
registers since 1976 all patients treated for leukemia, lymphoma, central nervous 
system (CNS) tumors, malignant solid tumors or Langerhans cell histiocytosis in one of 
the nine pediatric cancer centers in Switzerland. Since 1995 it registers more than 95% 
of all children diagnosed below age 16 years in Switzerland 15, 16. The registry contains 
detailed individual clinical information on medical history, cancer diagnosis, treatment 
and follow-up, including date and cause of death, if applicable (see paragraph below on 
“Outcome Measure: Mortality”) 14, 16. Diagnoses are coded according to the International 
Classification of Childhood Cancer, third revision (ICCC-3) 17.  
 
The Swiss National Cohort 
Information on socioeconomic status was retrieved from the Swiss National Cohort 
(SNC; www.swissnationalcohort.ch), which we described in detail elsewhere 18. In short, 
the SNC is a national longitudinal cohort of Switzerland based on deterministic and 
probabilistic linkage of Census data with mortality records. Participation in the Swiss 
census was mandatory and the coverage for the 2000 census was estimated to be 
98.6% 19. To examine the potential bias due to the record linkage we reanalyzed the 
SNC adding unlinked death records and found no effect on relative mortality estimates 
20. In this study, we used data from the Swiss census 1990 and 2000, which includes 
detailed information on family characteristics and socioeconomic determinants for all 
Swiss citizens. We further used a publicly available area-based SES index (SES index) 
as developed by the Department of Geography at the University of Zurich 21, which had 
been attached by the SNC to the census data.  
 
Linkage of the two data sources SCCR and SNC 
Because routine data in Switzerland are anonymous without personal identifiers, we 
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linked the cases from the SCCR to the SNC using a probabilistic linkage procedure. 
Information contained in both datasets (sex, date of birth and place of residence) were 
used for linking the records. Only cases born before, and diagnosed after a census were 
included in this study to avoid selection bias related to selective exclusion of children 
who had died before the census and thus could not have been registered. For children 
born before 1990 and diagnosed after 2000, we used the census 2000 data to assure 
that the information on socioeconomic status was contemporary and had always been 
collected prospectively, before the child had been diagnosed with cancer.  
 
Outcome Measure: Mortality  
The assembly of follow-up information and the ascertainment of mortality of the patients 
recorded in the SCCR, is done actively by data managers from the nine pediatric oncology 
centers of Switzerland for the duration of follow-up in outpatient clinics (generally 5 to 10 
years after diagnosis). During this time the data managers yearly report the date when 
patients were last known to be alive or date and causes of death if a patient has died. 
Additionally, information on mortality is updated regularly via comparisons with the 
National mortality statistics and through requests at the communities of residence.  
 
Explanatory variables: Indicators of Socioeconomic Status 
Because previous publications showed conflicting results depending on the definition of 
SES in use 22-24, we compared the effects of several variables collected in the census 
representing socioeconomic status. These included individual-based SES information 
(education of the mother or the father in the household), household-based information 
(number of rooms per person excluding kitchen and bathrooms, square meter living 
space per person), and a publicly available area-based SES index representing an 
average measure of net income, education level and job position of the population living 
in a respective area (community or quarter). For analysis, we categorized the two 
continuous variables living space and area-based SES index into tertiles. Parental 
education was grouped into “compulsory schooling or less” (up to 9 years of education), 
“secondary education” (10 to 16 years, high school, teachers training colleges, technical 
colleges and upper vocational education) and “tertiary education” (16 years or more, 
university degree). Number of habitable rooms per person was grouped into: “<1 room 
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per person” (more than 1 person per room = overcrowded), “1-1.25 room per person”, 
“>1.25 room per person” 25.  
 
Statistical Analyses 
For the 5-year survival analyses, follow-up time was calculated from date of diagnosis 
until date of death, the last date the patient was known to be alive or exactly 5 years 
after diagnosis, whichever came first. We calculated survival as cumulative mortality 
functions (one minus the Kaplan-Meier survival estimates), separately for each SES 
indicator, first for all cancers together and then stratified by main types of cancer 
(leukemia, acute lymphoblastic leukemia (ALL), lymphoma, central nervous system 
(CNS) tumors, bone and soft tissue tumors, and embryonal tumors). Univariable and 
multivariable Cox proportional hazards regression models were used to assess the 
association between survival and the different SES measures. We reported hazard 
ratios (HR) with 95% confidence intervals (95%CI). The multivariable Cox proportional 
hazards models included, in addition to the SES indicator: gender (male, female); age at 
diagnosis (0-4, 5-9, 10-13, 14-16); period of diagnosis (1991-1998, 1999-2006); and, for 
the model including all cancers, type of cancer (leukemia, ALL, lymphoma, CNS tumors, 
bone and soft tissue tumors, embryonal tumors). To calculate a p-value for trend over 
the SES levels, we included SES as a continuous variable coded from 1 to 3.  
 
For CNS tumors, we explored in additional analyses whether the strength of the SES 
survival association was reduced when including in serial manner baseline information 
known or suspected to be prognostic for survival. We defined baseline information as 
being prognostic for survival if they were associated with mortality in an univariable Cox 
Proportional Hazards regression model. We investigated the following prognostic 
information:: WHO staging (grade I, II, III and IV); histopathological tumor groups 
(PNET/Medulloblastoma; low-grade glioma; high-grade glioma; ependymoma; and 
others); first line therapy protocol (surgery only; chemotherapy with/without surgery; 
radiotherapy with/without surgery or chemotherapy; and, bone marrow transplantation); 
clinical trial participation status (study patient; not study patient but treated according to 
protocol; and, not treated according to a study protocol); localization (supratentorial 
hemispheric; supratentorial midline; infratentorial; and spinal) and, size of the treatment 
center (>40 patients/year vs. ≤40 patients/year).  
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All p-values are two sided and a p-value of ≤0.05 was considered as statistically 
significant. Statistical analyses were performed using STATA, version 12 (StataCorp. 
2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP).
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RESULTS 
Characteristics of the Study Population 
Overall, 1867 childhood cancer patients met the inclusion criteria for linkage with the 
census 1990 or 2000. From these we excluded 177 patients with rare or unspecific 
diagnoses (epithelial neoplasm; malignant melanomas; and, other or unspecified 
malignant tumors). For 94.8% (1602 of 1690) we had a date the patient was known to 
be alive, or a date of death. Of these, 56.8% were male, 47.9% were diagnosed after 
age 10 years, 33.0% (528) had been diagnosed with leukemia (399 with ALL), 22.1% 
(354) with a CNS tumor, 19.6% (314) with lymphoma, 14.4% (231) with a bone or a soft 
tissue tumor, and 10.9% (175) with an embryonal tumor (Tables 1 and S1).  
 
Socioeconomic Status and Survival 
All types of cancer 
In the whole population (N=1602) including all diagnostic groups, we calculated a 
cumulative five year mortality of 23% (95% confidence interval (95%CI) 21-25), highest 
for patients with CNS tumors (31%; 95%CI 26-35) and lowest for lymphoma patients 
(8%; 95%CI 5-11). Multivariable cox regression models (including all diagnostic groups) 
showed higher survial (with higher hazard ratios across all SES indicators) in the 
highest socioeconomic group (Table 2, first column and Figure 1, first graph). P-values 
for trend were below 0.1 for paternal education, maternal education and living space 
(Table 2). Results were similar in the univariable (Table S2) and the multivariable 
(Table 2) models.  
 
Survival from Leukemia 
For leukemia patients (N=528) both univariable and multivariable models showed no clear 
evidence for an association between SES and survival, with hazard ratios close to one and 
all p-values for trend >0.2 (Tables 2 and S2, second column; Figure 1, second graph). 
Results of a sensitivity analysis including only 399 ALL survivors were comparable (Tables 
S3 and S4, first column).  
 
Survival from CNS tumors 
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For survivors of CNS tumors (N=354) there was strong evidence for a lower survival in 
the lowest socioeconomic group (Tables 2 and S2, fourth column). This applied to all 
SES indicators but was strongest for paternal (Figure 1, graph 4) and maternal 
education, with hazard ratios of 0.48 and 0.52, respectively, and p-values for trend of 
0.008 and 0.014, respectively; comparing the highest with the lowest group of education 
in the multivariable cox models (Table 2). The association was somewhat weaker with 
household-based SES measures with a HR of 0.56 (p=0.023) for rooms per person and 
0.61 (p=0.056) for living space; and weakest for the area-based SES index (HR 0.71 for 
the highest tertile, p=0.170). Results were similar in the univariable regression model 
(Table S2).  
 
As SES disparities in childhood cancer survival were most prominent in CNS patients, we 
characterized the CNS tumor patients in more detail and explored in additional analyses 
whether these survival differences could be explained by different clinical baseline 
information (Table 3). Among patients of CNS tumors, most were classified as grade I 
(41%) or IV (33%) by the WHO, had a tumor histology of low-grade glioma (42%) or 
PNET/Medulloblastoma (24%) and had an infratentorial localization (53%). About half 
(49%) were treated with surgery only and 37% with radiotherapy. Almost half of the CNS 
patients (48%) had not been treated according to a protocol and two thirds had been 
treated in a large treatment center with more than 40 childhood cancer patients per 
year. 
 
In the univariable model, WHO grade, histology, therapy and trial participation were all 
significantly associated with survival (Table 3), while tumor localization and size of the 
treatment center were not associated. Therefore, tumor localization and size of the 
treatment center were no longer included in the multivariable models to further explore the 
relationship between survival and SES in CNS tumor patients. When including in serial 
manner the other variables (WHO grade, histology, therapy, and clinical trial participation) 
in the multivariable models, the hazard ratio of the SES- survival association in CNS 
patients remained almost unaffected (Table 4).  
 
Survival from lymphoma, embryonal tumors, bone tumors and soft tissue sarcoma 
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Comparable to the leukemia patients, almost no association between survival and SES 
levels was found for embryonal tumors, and bone tumor and soft tissue sarcoma in 
multivariable and univariable cox regression models (Tables S3 and S4, second and 
third columns; Figure 1, last two graphs). Results for lymphoma were more comparable 
to those found for CNS tumor patients (Tables 2 and S2, third column; Figure 1, third 
graph). However, due to lower patient numbers only the association between paternal 
education and survival in lymphoma patients was statistically significant (p=0.018) 
(Table 2). 
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DISCUSSION 
In this study we found strong evidence for a deprivation gap in survival of patients with 
CNS tumors, with survival reduced to half in children from not well-educated families. 
This is the first population-based study on childhood cancer survival and socioeconomic 
status of the family that considered several SES indicators collected prospectively in the 
census before the child’s cancer diagnosis. The results were consistent across all SES 
indicators but most pronounced for paternal and maternal education, and were not readily 
explained by differences in clinical baseline information or other measures at hand. For 
other cancer diagnoses, SES disparities in childhood cancer survival were less evident 
and for leukemia we found none.  
 
Comparison with other studies 
For childhood cancer, data on survival and socioeconomic status of the family are 
scarce and contradictory. In a recent systematic review the authors showed that, while 
mostly older studies found no evidence for a change in childhood cancer survival by 
SES, many newer studies found survival rates to be lower in the deprived 
socioeconomic groups 8. They further established the fact that survival in patients of 
childhood cancer varies by type of cancer and SES indicator in use and the socio-
cultural context of the patient’s country of residence. The overall study’s results on 
childhood cancer survival differentials accentuate the importance to examine different 
definitions of SES and their distinct associations with cancer types and clinical markers. 
Especially, when considering the fact that childhood cancer survival, besides tumor type 
and the child’s response to treatment, seems to be mainly explained by differences in 
patient’s tumor stage and the applied therapy 26, 27, and both these factors have shown 
to be differently influenced by socioeconomic status, depending on the SES definition in 
use 8, 28. However, an international comparison of study findings in this context is difficult 
due to dissimilarities in welfare systems, including access to health care and public 
family support, coverage and distance to treatment facilities, lifestyle and socio-cultural 
aspects and methodological differences between studies. 
 
Interestingly, we found no clear trend between survival and SES for leukemia, although 
this was the largest diagnostic group. Our results were corroborated by a recent 
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German study which found that socioeconomic factors were not related to ALL survival 
in children 29. They claimed their results to be plausible by the fact that irrespective of 
coverage by private or statutory health insurance (Germany has a similar universal 
health care system like Switzerland with two main types of health insurance: private 
insurance and statutory health insurance) and of social background, all children and 
adolescents have free access to health care. Additionally, they stated that more than 
90% of all pediatric oncology patients are included in clinical trials of therapy 
optimization studies in Germany. This is as well comparable to Switzerland where 73% 
of the childhood leukemia patients are included in clinical trials and about 92% of the 
patients are treated according to a study protocol. Nevertheless, recent European 
studies found children with childhood leukemia from a lower parental socioeconomic 
level to experience worse survival 26, 30, 31.  
 
To our knowledge, only a few US-based studies, using data from the Surveillances, 
Epidemiology and End Results (SEER) Program, focused on brain tumor survival in 
children. Two reported a lower survival in African Americans 32, particularly for 
astrocytomas 33. The third found only trends by race for certain histological subtypes, 
despite a sample size of 2799 34. In an English study, CNS tumor survival was 
influenced only by age, morphology and stage, but not socioeconomic status and region 
35.  
Generally, our findings fit well into the literature, but the large survival gap found for 
CNS tumors, with survival reduced to half in children of low educated parents, sticks 
out. Similar findings were only reported from South Korea 28, 36 The survival gap we 
found was considerably larger than what has been reported in US studies. A main 
reason might be the much lower number of Swiss children with CNS tumors being 
included in clinical trials (25.7%) and treated according to a study protocol (45.4%), 
when compared with childhood leukemia patients. Another reason might be the 
inclusion of individual and household-based SES in our study, additionally to the 
commonly used area-based SES indicators. The survival differentials were in fact 
smaller for household-based SES indicators and disappeared for the area-based 
indicator. In analogy, an English study found smaller deprivation gaps in survival of adult 
cancer for large compared to small geographic units, suggesting a dilution effect caused 
by aggregated exposure measures 37. The common use of area-based SES indicators 
might have diluted survival differentials in many studies. 
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Potential underlying causes of survival differences in CNS tumor patients  
SES disparities in cancer outcome have been explained by three main causes 27, 38. 
First, tumor characteristics, particularly differences in stage at diagnosis caused by 
longer patient or health provider delay 39, 40, misclassification of stage because of less 
thorough diagnostic work-up, or differences in biological tumor characteristics 41, 42. 
Second, patient characteristics, particularly differences in comorbidity, risk behaviors, 
nutrition and psychosocial factors. Third, differences in treatment, by availability of 
specialist medical expertise or differences in patient adherence.  
 
Many studies in adults and children have in fact suggested that once treatment is equal, 
as in clinical trials or highly specialized clinics, SES disparities disappear 41-43. 
Comorbidities and health behaviors are unlikely to play a major role in young children. 
Even in adults, studies looking at relative survival stratified by socioeconomic groups, 
e.g. compensating for differences in background mortality suggest that comorbidities 
play a minor role 44.   
 
In our study, we tried to assess the effect of underlying causes as explanatory factors 
for our findings. Adjustment for WHO grade at diagnosis, histological type and 
localization did not eliminate the gap in CNS tumor survival, suggesting that delayed 
diagnosis or differences in tumor morphology or topography between social groups did 
not play an important role 39, 40. However, we could include only basic measures and 
residual confounding is possible. We also tested whether differences in initial treatment 
or inclusion in a clinical trial explained our findings. Adjustment for these factors did not 
attenuate but, if anything, accentuate the survival gap. However, the treatment data we 
had was limited. 
 
In Switzerland almost all children and adolescents with cancer are treated in one of the 
nine pediatric oncology centers. In contrast to leukemia therapy, the treatment of brain 
and spinal tumors usually necessitates a very interdisciplinary team including the 
pediatric oncologist, neurosurgeons and radiotherapists. Usually the latter two 
professional groups are not pediatric specialists, with exception of specialists in the two 
largest Swiss centers. Treatment within study protocols and the clinical decision making 
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process (case discussion in tumor boards, inclusion of national or even international 
experts) become more and more important, as early diagnosis and therapy (essentially 
surgery) are of crucial relevance for the therapy success of childhood cancer. In the last 
twenty-five years over ninety percent of the leukemia patients had been treated by an 
international standardized protocol, but less than half of the CNS tumor patients. In 
summary, in comparison with leukemia, CNS tumors are more heterogeneous, have 
less standardized treatment and typically involve complex, high-skill surgery, 
necessitating pediatric intensive care admission. Although our data do not allow proving 
this, we think that ability of wealthier and higher educated parents to obtain second 
opinion evaluations, better access to a more thorough diagnostic work-up in treatment 
centers of excellence and higher referral to highly skilled neurosurgeons, radiotherapists 
and oncologists, could explain our findings. However, such associations are speculative 
and remain to be assessed in future evaluations. 
 
Strengths and Limitations 
Our study design allowed overcoming several limitations of earlier studies on SES and 
childhood cancer survival. First, the study was nationwide and largely avoided participation 
bias. We included all cases of the national childhood cancer registry fulfilling the inclusion 
criteria for linkage with the census. Second, we obtained information on socioeconomic 
status from the census, avoiding reporting bias. Due to the conditions for linkage (the 
children had to be born before and diagnosed after the census), the information on SES 
was always collected prospectively, before the child had been diagnosed. This eliminated 
the possibility of differential reporting by parents of cured and deceased children, and 
made sure that the exposure preceded the outcome, i.e. that the SES did not change as a 
consequence of the diagnosis. Third, the availability of different definitions of 
socioeconomic status with data on individual-based (parental education), household-based 
(number of rooms per person, square meter living space per person) and area-based 
SES information is a unique feature of our study. It allowed assessing the robustness of 
our findings and analyzing potential differences between the examined SES proxies 22-24. 
Last, the availability of detailed clinical information allowed exploring pathways in 
anadditional analysis of CNS tumor patients. The study has also limitations. First, we 
excluded children born after 1990 and diagnosed before 2000, potentially introducing 
selection bias not including children born and diagnosed between the two censuses. 
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Nevertheless, as survival might be linked to SES, including these children may on the 
other hand have introduced survivor bias. Second, although we included many SES 
proxies in the analysis, we lacked a direct measure of income or wealth. Third, our sample 
size, although nationwide, was reduced by the linkage design, due to missings in the 
cancer registration and missing patient follow up information (5-10% of all patients), 
resulting in limited statistical power for analyzing diagnostic subgroups. In addition, the 
data linkage resulted in a higher proportion of patients with older age at diagnosis, so that 
relative frequencies of different tumors, and age-sex distribution in our sample differed 
somewhat from a random, sample of pediatric cancer patients. This should, however, not 
have affected our findings on the association between SES and survival. Fourth, we 
assessed the effect of different SES measures individually, and did not develop a score or 
conjunct measure of SES. Therefore, the total burden of mortality explained by lower 
socioeconomic status might in fact be even bigger than our results suggest. Last, we had 
no information on minor comorbidities, health behaviors, social support and patients’ 
adherence to treatment, and the available information on staging, biological prognostic 
factors and treatment was only basic, leaving room for residual confounding. 
 
Conclusions and implications  
In this study, conducted in a high-income country with mandatory health insurance, a 
high quality health care system and high absolute cancer survival rates, we found a 
large socioeconomic gap in survival of pediatric CNS tumors. The lack of SES 
disparities in leukemia, where treatment is highly standardized and most patients are 
included in clinical trials suggests that the gap found for CNS tumor patients may be 
explained by differences in the therapeutic process. Complete elimination of the survival 
differences would lead to an overall 5-year survival of 75% for CNS tumors, the risk 
observed in the least deprived SES group. Every effort should therefore be made to 
understand the reasons for the detected survival differences, to improve early diagnosis 
and facilitate universal access to state-of-the-art treatment in all countries, in order to 
reduce socioeconomic inequalities and international differences in childhood cancer 
survival. 
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Figure 1. Cumulative mortality over the first 5 years after cancer diagnosis by education level 
of the father, overall and by type of cancer 
 
Figure legend: CNS = Central Nervous System 
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Table 1. Characteristics of the Study Population: Overall and by Type of Tumor (see 
online Table S1 for Embryonal Tumors, and Bone and Soft Tissue Tumors) 
 All diagnoses (N=1602) 
Leukemia 
(N=528) 
Lymphoma 
(N=314) 
CNS Tumors 
(N=354) 
Characteristics N %a N %a N %a N %a 
Demographic 
characteristics         
Gender         
Male 910 56.8 317 60.0 197 62.7 186 52.5 
Female 692 43.2 211 40.0 117 37.3 168 47.5 
Age at diagnosis (years)         
0-4 318 19.9 148 28.0 20 6.4 57 16.1 
5-9 516 32.2 174 33.0 83 26.4 151 42.7 
10-13 519 32.4 144 27.3 124 39.5 107 30.2 
14-16 249 15.5 62 11.7 87 27.7 39 11.0 
Period of diagnosis         
1991-1994 462 28.8 174 33.0 79 25.2 82 23.2 
1995-1998b 276 17.2b 88 16.7b 66 21.0b 62 17.5b 
1999-2002 421 26.3 131 24.8 82 26.1 100 28.3 
2003-2006 443 27.7 135 25.6 87 27.7 110 31.1 
Census data used         
1990 841 52.5 282 53.4 173 55.1 163 46.1 
2000 761 47.5 246 46.6 141 44.9 191 54.0 
Socioeconomic 
characteristics         
Education status of the 
father         
Compulsory education 304 20.0 109 21.8 69 23.6 60 17.9 
Secondary education 726 47.9 243 48.7 136 46.4 152 45.4 
Tertiary education 487 32.1 147 29.5 88 30.0 123 36.7 
Missing 85  29  21  19  
Education status of the 
mother         
Compulsory education 468 29.4 156 29.7 98 31.5 95 27.0 
Secondary education 939 58.9 297 56.5 188 60.5 214 60.8 
Tertiary education 187 11.7 73 13.9 25 8.0 43 12.2 
Missing 8  2  3  2  
Rooms per person         
< 1 room/person 442 27.7 144 27.6 93 29.7 91 25.8 
1-1.25 rooms/person 583 36.6 192 36.8 99 31.6 146 41.4 
> 1.25 rooms/person 568 35.7 186 35.6 121 38.7 116 32.9 
Missing 9  6  1  1  
Living space (in m2)         
Lower tertile 467 33.8 155 34.7 93 33.9 101 33.3 
Medium tertile 457 33.1 139 31.1 92 33.6 100 33.0 
Upper tertile 457 33.1 153 34.2 89 32.5 102 33.7 
Missing 221  81  40  51  
Area-based SES index         
Lower tertile 545 34.0 164 31.1 116 36.9 116 32.8 
Medium tertile 541 33.8 199 37.7 100 31.9 112 31.6 
Upper tertile 516 32.2 165 31.3 98 31.2 126 35.6 
Abbreviations: CNS, Central Nervous System; N, Number; P, P-value; SES, Socioeconomic Status  
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a Proportions are calculated based on available information within each characteristic.  
b Small proportion of cancer diagnoses in this period because of fewer linkable cancer survivors with the 
Census dataset. 
  
Published in final edited form as: Int J Cancer. 2016 Jun 15;138(12):2856-66. doi: 10.1002/ijc.30029 
 
      23 
Table 2. Association between SES Indicators and Mortality (Multivariable Cox Proportional Hazard Models): Overall and by Type of 
Tumor (see online Table S2 for Results of the Univariable Cox Models) 
 All diagnostic groupsa (N=1602) Leukemia (N=528) Lymphoma (N=314) CNS Tumors (N=354) 
SES HRb (95%CI) P Pc HRd (95%CI) P Pc HRd (95%CI) P Pc HRd (95%CI) P Pc 
Education status of the father    0.036    0.234    0.018    0.008 
Compulsory education 1    1    1    1    
Secondary education 0.85 (0.64-1.11) 0.226  1.39 (0.81-2.38) 0.228  0.40 (0.16-1.02) 0.055  0.62 (0.38-1.01) 0.055  
Tertiary education 0.72 (0.53-0.98) 0.034  1.45 (0.82-2.58) 0.201  0.26 (0.08-0.85) 0.025  0.48 (0.28-0.81) 0.006  
Education status of the mother    0.020    0.830    0.287    0.014 
Compulsory education 1    1    1    1    
Secondary education 0.81 (0.65-1.02) 0.078  1.06 (0.69-1.61) 0.797  0.71 (0.30-1.66) 0.428  0.59 (0.39-0.90) 0.013  
Tertiary education 0.67 (0.45-0.98) 0.039  1.05 (0.58-1.91) 0.871  0.40 (0.05-3.19) 0.385  0.52 (0.26-1.05) 0.070  
Rooms per person    0.111    0.406    0.060    0.023 
< 1 room/person 1    1    1    1    
1-1.25 room/person 0.76 (0.59-0.98) 0.032  0.89 (0.55-1.43) 0.630  0.88 (0.35-2.23) 0.795  0.61 (0.39-0.97) 0.035  
> 1.25 room/person 0.80 (0.62-1.04) 0.095  1.19 (0.76-1.87) 0.454  0.35 (0.12-1.06) 0.062  0.56 (0.34-0.92) 0.021  
Living space (in m2)    0.072    0.975    0.062    0.055 
Lower tertile 1    1    1    1    
Medium tertile 0.78 (0.60-1.02) 0.075  0.97 (0.59-1.58) 0.888  0.61 (0.22-1.70) 0.349  0.71 (0.43-1.17) 0.174  
Upper tertile 0.78 (0.60-1.03) 0.076  1.01 (0.62-1.63) 0.981  0.31 (0.08-1.11) 0.072  0.61 (0.37-1.01) 0.053  
Area-based SES index    0.725    0.795    0.430    0.170 
Lower tertile 1    1    1    1    
Medium tertile 0.93 (0.71-1.20) 0.568  0.90 (0.56-1.42) 0.641  1.09 (0.38-3.09) 0.871  0.70 (0.43-1.15) 0.159  
Upper tertile 0.95 (0.73-1.24) 0.723  1.06 (0.66-1.71) 0.797  1.51 (0.55-4.16) 0.427  0.71 (0.44-1.15) 0.161  
Abbreviations: 95%CI, 95% Confidence Interval; CNS, Central Nervous System; HR, Hazard Ratio; N, Number; P, P-value; SES, Socioeconomic Status 
a Included ICCC-3 diagnoses: leukemia, lymphoma, CNS tumors, embryonal tumors, malignant bone and soft tissue tumors.  
b Adjusted for: diagnostic group, gender, age at diagnosis, period of diagnosis. 
c Two-sided p-value for test of trend. 
d Adjusted for: gender, age at diagnosis, period of diagnosis. 
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Table 3. Clinical Characteristics of Patients with Central Nervous System Tumors, and Hazard Ratios for 
the Association of these Characteristics with Mortality (N=354) 
Clinical characteristics N %a HR (95%CI) P Pb 
WHO grade      <0.001 
I 132 41.4 1    
II 45 14.1 5.97 (1.80-19.83) 0.004  
III 37 11.6 42.80 (14.89-123.02) <0.001  
IV 105 32.9 19.36 (6.98-53.73) <0.001  
Missing 35      
Histology      <0.001 
PNET/Medulloblastoma 84 23.9 1    
Low-grade glioma 146 41.5 0.14 (0.07-0.30 <0.001  
High-grade glioma 59 16.8 5.15 (3.25-8.16) <0.001  
Ependymoma 17 4.8 1.26 (0.58-2.75) 0.556  
Others 46 13.1 0.51 (0.24-1.07) 0.074  
Missing 2      
Localization      0.178 
Supratentorial hemispheric 67 19.1 1    
Supratentorial midline 84 24.0 0.87 (0.47-1.61) 0.651  
Infratentorial 186 53.1 1.29 (0.77-2.15) 0.327  
Spinal 13 3.7 0.48 (0.11-2.06) 0.322  
Missing 4      
Therapy      <0.001 
Surgery only 161 48.5 1    
Chemotherapyc 40 12.1 6.10 (3.11-11.97) <0.001  
Radiotherapyd 122 36.8 5.24 (3.00-9.14) <0.001  
BMT 9 2.7 2.22 (0.51-9.66) 0.287  
Missing 22      
Participation to clinical trial      0.001 
Study patient according to protocol 110 31.4 1    
Non-study patient according to protocol 73 20.9 2.65 (1.57-4.48) <0.001  
Non-study patient not according to protocol 167 47.7 1.38 (0.83-2.28) 0.210  
Missing 4      
Size of the treatment centre      0.407 
>40 patients 233 65.8 1    
≤40 patients 121 34.2 0.85 (0.57-1.25)   
Abbreviations: 95%CI, 95% Confidence Interval; BMT, Bone Marrow Transplantation; HR, Hazard Ratio; N, Number; 
P, P-value  
a Proportions are calculated based on available information within each characteristic.  
b Two-sided global p-value from likelihood ratio test. 
c Without radiotherapy, may have had surgery. 
d May have had surgery or chemotherapy. 
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Table 4. Influence of Tumor Stage and Treatment on SES Differential in CNS Tumor Mortality (N=354) 
 CNS Tumors (N=354) + WHO grade + histology + therapy + study participation 
SES HRa (95%CI)  Pb HRc (95%CI)  Pb HRc (95%CI)  Pb HRc (95%CI)  Pb HRc (95%CI)  Pb 
Education father    0.008    0.013    0.184    0.012    0.016 
Compulsory  1    1    1    1    1    
Secondary  0.62 (0.38-1.01)   0.60 (0.35-1.03)   0.64 (0.39-1.04)   0.68 (0.40-1.16)   0.68 (0.41-1.12)   
Tertiary  0.48 (0.28-0.81)   0.47 (0.26-0.85)   0.68 (0.40-1.16)   0.48 (0.27-0.85)   0.51 (0.30-0.87)   
Education mother    0.014    0.146    0.181    0.100    0.015 
Compulsory  1    1    1    1    1    
Secondary  0.59 (0.39-0.90)   0.60 (0.38-0.97)   0.74 (0.48-1.14)   0.72 (0.46-1.14)   0.60 (0.39-0.91)   
Tertiary  0.52 (0.26-1.05)   0.78 (0.35-1.77)   0.70 (0.34-1.42)   0.56 (0.24-1.31)   0.50 (0.24-1.05)   
Rooms per person    0.023    0.197    0.014    0.056    0.051 
< 1 room/person 1    1    1    1    1    
1-1.25 room/person 0.61 (0.39-0.97)   0.76 (0.44-1.29)   0.65 (0.40-1.06)   0.70 (0.43-1.15)   0.59 (0.37-0.95)   
> 1.25 room/person 0.56 (0.34-0.92)   0.69 (0.39-1.22)   0.52 (0.32-0.87)   0.59 (0.34-1.01)   0.61 (0.37-0.99)   
Living space (in m2)    0.055    0.176    0.035    0.097    0.088 
Lower tertile 1    1    1    1    1    
Medium tertile 0.71 (0.43-1.17)   0.80 (0.46-1.40)   0.79 (0.47-1.32)   0.82 (0.48-1.40)   0.74 (0.45-1.23)   
Upper tertile 0.61 (0.37-1.01)   0.67 (0.38-1.20)   0.58 (0.35-0.96)   0.63 (0.36-1.09)   0.64 (0.38-1.08)   
Area-based SES index    0.170    0.791    0.929    0.312    0.148 
Lower tertile 1    1    1    1    1    
Medium tertile 0.70 (0.43-1.15)   0.75 (0.43-1.32)   0.90 (0.55-1.48)   0.68 (0.39-1.18)   0.64 (0.38-1.08)   
Upper tertile 0.71 (0.44-1.15)   0.92 (0.53-1.61)   0.98 (0.59-1.61)   0.75 (0.45-1.27)   0.69 (0.42-1.12)   
Abbreviations: 95%CI, 95% Confidence Interval; CNS, Central Nervous System; HR, Hazard Ratio; N, Number; P, P-value; SES, Socioeconomic Status 
a Adjusted for: gender, age at diagnosis, period of diagnosis. 
b Two-sided p-value for test of trend. 
c Adjusted for: gender, age at diagnosis, period of diagnosis plus one at a time: WHO grade, histology, therapy or study participation.  
